secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001193125-25-032821
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase acquires CorHepta for $15M in stock; appoints Cabell as President and Adams as CSO
--------------------------------------------------------------------------------

- Acquired CorHepta for $15M in stock: 4,979,101 shares issued (3,319,397 upfront, remainder contingent on milestone).
- Chris Cabell appointed President & Head of R&D; former CorHepta CEO and ex-CMO of Arena Pharmaceuticals.
- Vincent Aurentz appointed to Board; former EVP/Chief Business Officer at Arena (acquired by Pfizer for $6.7B).
- John Adams appointed Chief Scientific Officer; co-founder of CorHepta, former Head of Research at Arena.
- Dr. Cabell employment: $500K base, 45% bonus, 2.81M stock options vesting over 4 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/0001193125-25-032821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/d889659d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-032821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer